Drug intelligence / Profile preview

TRX-105

Development stage: Preclinical
Lead developer: TaiRx
Modality: Small Molecules
Administration: Oral

Overview

**TRX-105** is an orally administered, known small-molecule drug being repurposed by TaiRx for new therapeutic uses in colitis and enterocolitis. TaiRx describes preclinical animal-model activity showing reductions in inflammatory colonic swelling and intestinal ulceration, along with restoration of damaged intestinal membrane, compared with mesalazine as a reference treatment. The specific chemical identity, molecular target, and detailed mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on TRX-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRX-105.

Explore the full profile